Studies 2017-12-13T08:24:51+00:00

Studies

Thank you for your interest in volunteering for one of the University of Southern California Alzheimer’s Therapeutic Research Institute (USC ATRI) coordinated studies.

To participate, please find a trial that is right for you (or someone you love) and contact a clinical site near you. Each of our studies have different eligibility criteria.  While not everyone can join a trial, you can always become an advocate by sharing the trials with someone you know who might be able to participate.

To watch an informational video about why your participation in clinical trials is so important, click here.

We appreciate your support as we seek to prevent and treat Alzheimer’s disease.

Active Studies – Recruiting

ADNI3

adni-logo

The Alzheimer’s Disease Neuroimaging Initiative (ADNI), a landmark study that began in 2004, is a public-private research partnership tasked with identifying biomarkers to detect Alzheimer’s disease (AD). The study has gathered and analyzed thousands of brain scans, genetic profiles and biomarkers in blood and cerebrospinal fluid (CSF) and was designed to enable researchers to follow AD as it progresses in an individual, from various points in the disease process.  ADNI3 will include 600 new participants age 55-90 and 600 rollover participants from ADNI2.

Learn more »

DOD ADNI STUDY

brain-aging

The purpose of DOD ADNI is to examine the possible connections between Traumatic Brain Injury (TBI) and Posttraumatic Stress Disorder (PTSD), and the signs and symptoms of AD on Veterans as they age. Approximately 300 Vietnam War Veterans, ages 50-90 will be eligible to participate in this study

Learn more »

EARLY

early-clinical-trial-logo

The EARLY Trial will use the latest advances to assess a participant’s risk associated with beta-amyloid and memory loss, and will test whether a treatment that reduces amyloid formation will slow memory loss associated with Alzheimer’s disease (AD). We are looking for healthy people who are age 60 to 85 years, do not have any symptoms of the disease, but may be at risk for developing the memory and cognitive symptoms of AD.

Learn more »

MIND

mind-logo

The purpose of the Memory Improvement Through Nicotine Dosing (MIND) study is to determine whether daily transdermal nicotine (patch) will have a positive effect on early memory impairment in participants diagnosed with Mild Cognitive Impairment (MCI).  We are looking for healthy, non-smoking adults, age 55+.

Learn more »

Active Studies – Recruitment Completed

THE A4 STUDY

A-study

If you are a healthy older adult with normal memory, now is the time to join the fight to prevent Alzheimer’s disease. The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the A4 Study) is a clinical trial for adults ages 65-85 who have normal thinking and memory function but who may be at risk for Alzheimer’s due to family history of the disease and elevated levels of amyloid plaque in the brain. The study aims to prevent the memory loss associated with the disease.

Learn more »

ADNI-D

ADNI-D Study Logo

If you are age 65 or older and currently experiencing symptoms of depression, you may be a candidate to participate in the ADNI Depression Project. The goal of this study is to determine whether imaging of the brain can help predict the onset and monitor the progression of cognitive change

Learn more »

CONNECT STUDY

CONNECT_Logo

The CONNECT study is testing whether an oral, experimental drug, AZD0530 (saracatinib), will slow progression in early stage Alzheimer’s disease (AD). In its early stage after the medical diagnosis of Alzheimer’s disease, patients typically show some memory loss but a majority of daily functions are intact, requiring some reminders or help organizing the day from others in the household.

Learn more »

SNIFF STUDY

SNIFF_Logo

The purpose of the SNIFF study is to find out whether a type of insulin, when administered as a nasal spray, improves memory in adults with a mild memory impairment or Alzheimer’s disease (AD). We are looking for 250 adults age 55-85 diagnosed with amnestic mild cognitive impairment (aMCI) or early AD.

Learn more »